C
Corey A. Siegel
Researcher at Dartmouth–Hitchcock Medical Center
Publications - 340
Citations - 10537
Corey A. Siegel is an academic researcher from Dartmouth–Hitchcock Medical Center. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 44, co-authored 272 publications receiving 8196 citations. Previous affiliations of Corey A. Siegel include Dartmouth College & Harvard University.
Papers
More filters
Journal ArticleDOI
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Laurent Peyrin-Biroulet,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Walter Reinisch,Willem A. Bemelman,Robert V Bryant,G R D’Haens,Iris Dotan,Marla Dubinsky,Brian G. Feagan,Gionata Fiorino,Richard B. Gearry,S. Krishnareddy,Peter L. Lakatos,Edward V. Loftus,P. Marteau,Pia Munkholm,Travis B. Murdoch,Ingrid Ordás,Remo Panaccione,Robert H. Riddell,J. Ruel,David T. Rubin,Mark A Samaan,Corey A. Siegel,Mark S. Silverberg,Jaap Stoker,Stefan Schreiber,Simon Travis,G. Van Assche,G. Van Assche,Silvio Danese,Julián Panés,Guillaume Bouguen,Sarah O’Donnell,Benjamin Pariente,S. Winer,Stephen B. Hanauer,J.-F. Colombel +39 more
TL;DR: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available and future studies are needed to determine how these targets will change disease course and patients’ quality of life.
Journal ArticleDOI
ACG Clinical Guideline: Ulcerative Colitis in Adults
TL;DR: These guidelines indicate the preferred approach to the management of adults with UC and represent the official practice recommendations of the American College of Gastroenterology.
Journal ArticleDOI
Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel,Corey A. Siegel,Sadie M. Marden,Sarah Persing,Robin J. Larson,Bruce E. Sands +5 more
TL;DR: The use of anti-TNF agents with immunomodulators is associated with an increased risk of NHL in adult CD patients, but the absolute rate of these events remains low and should be weighed against the substantial benefits associated with treatment.
Journal ArticleDOI
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
Uma Mahadevan,Douglas C. Wolf,Marla Dubinsky,Antoine Cortot,Scott D. Lee,Corey A. Siegel,Thomas A. Ullman,Sarah C. Glover,Sarah C. Glover,John F. Valentine,David T. Rubin,Jocelyn Miller,Maria T. Abreu +12 more
TL;DR: CZP has the lowest level of placental transfer, based on levels measured in cords and infants at birth, of the drugs tested; the TNF antagonists IFX and ADA are transferred across the placenta and can be detected in babies at birth.
Journal ArticleDOI
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens,Remo Panaccione,Peter D.R. Higgins,Severine Vermeire,Miquel A. Gassull,Yehuda Chowers,Stephen B. Hanauer,Hans H Herfarth,Daan W. Hommes,Michael A. Kamm,Michael A. Kamm,Robert Löfberg,A. Quary,Bruce E. Sands,Ajit Sood,G. Watermayer,Bret A. Lashner,Marc Lémann,Scott E. Plevy,Walter Reinisch,Stefan Schreiber,Corey A. Siegel,S. R. Targan,Mamoru Watanabe,Brian G. Feagan,William J. Sandborn,Jean-Frederic Colombel,Simon Travis +27 more
TL;DR: Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment, and there are insufficient data to make recommendations on when to stop anti-TNF therapy.